What are the specific contraindications of Besudil/Yilaike and what should be paid attention to when using it?

Belumosudil mesylate tablets (Belumosudil) is a small molecule oral drug targeting the ROCK2 pathway. It is mainly used to treat chronic graft-versus-host disease after hematopoietic stem cell transplantation. Since its mechanism of action is directly involved in immune regulation, it is particularly important to identify contraindications and risk groups during use. Judging from the instructions and medication interpretation, Besudil is not suitable for all patients, and reasonable evaluation is the prerequisite for safe medication.

First of all, patients with a clear history of allergy to besudil or any of its excipients are generally considered to be contraindicated in its use. Although this type of situation is uncommon, once it occurs, it may cause immune-related reactions such as rash, respiratory discomfort, etc., and requires immediate discontinuation and treatment. Secondly, besudil needs to be used with extreme caution in patients with severe hepatic impairment. Data point out that the drug is mainly metabolized by the liver. If the basic liver function is obviously abnormal, it may increase the risk of drug accumulation in the body. Therefore, it is usually not recommended to be used in cases of severe liver damage, or its use needs to be weighed under close monitoring by a professional doctor.

In terms of medication precautions, Besudil, as an immunomodulatory drug, may affect the body's defense against infection. Although it is not a strong immunosuppressant in the traditional sense, drug experience still emphasizes that treatment should be initiated with caution before active infection is under control. In addition, for patients who are taking other immunomodulatory or anti-rejection drugs concurrently, the potential risk of interaction needs to be evaluated to avoid excessive suppression of immune function or mutual interference with efficacy.

Special populations are also an important part of medication evaluation. At present, Besudil is mainly suitable for patients who are 12 years old and above and whose weight reaches a certain standard. For children, pregnant women and lactating people, there is generally a lack of sufficient safety data, so it is usually not recommended as a routine target.

Reference: https://www.drugs.com/pro/rezurock.html